-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shisi Pharmaceutical Group Honored as the Most Promising Growth-Oriented Biopharmaceutical Listed Company
Category:
发布时间：2022-12-29
【概要描述】
On December 28, at the 11th China Listed Companies Summit Forum hosted by the leading financial media outlet Daily Economic News, the 2022 12th China Listed Companies Reputation Rankings were officially unveiled, with Shisi Pharmaceutical Group honored as the Most Promising Growth-Oriented Biopharmaceutical Listed Company.
On December 28, at the 11th China Listed Companies Summit Forum hosted by the leading financial media outlet Daily Economic News, the prestigious 2022 12th China Listed Companies Reputation Rankings were officially unveiled, with Shisi Pharmaceutical Group honored as the Most Promising Growth-Oriented Biopharmaceutical Listed Company.
According to reports, the Daily Economic News has been organizing the Listed Companies Reputation Rankings for 12 years, making it one of the most influential and prestigious events in the industry. The rankings are determined through a rigorous four-stage process: public nominations, big-data screening, model-based evaluation, and voting by institutional investors and the general public. Ultimately, more than 100 outstanding companies are selected from thousands of listed firms to receive recognition. Among these, the “Most Promising Biopharmaceutical Listed Company” award has long been regarded as one of the most prestigious honors in the sector, with fierce competition each year. Shisi Pharmaceutical Group’s inclusion on the list is a clear testament to the company’s strong performance in innovation, market execution, commercial value, and growth potential, earning widespread acclaim from investors and the capital markets.
As a major backbone enterprise in China’s pharmaceutical industry, Shisi Pharmaceutical Group has, in recent years, leveraged its core strengths and focused on the overarching theme of transformation, upgrading, quality improvement, and efficiency enhancement. Guided by innovative development, the company has actively implemented a coordinated “four-wheel-drive” strategy encompassing generic drugs, active pharmaceutical ingredients, innovative medicines, and pharmaceutical packaging materials. By significantly increasing investment in innovation and drawing on high-level research platforms such as the national-level Enterprise Technology Center and the National–Local Joint Engineering Laboratory—both of which integrate industry, academia, research, and application—the Group has established a comprehensive, scientifically sound, and well-defined pathway for technological innovation and product development. It has continuously expanded its presence and intensified efforts in areas such as first-generic drugs, innovative medicines, specialty APIs, pharmaceutical packaging materials, and high-end complex formulations, thereby consistently driving the company’s high-quality growth. Since the beginning of this year, Shisi Pharmaceutical Group has ranked among the top pharmaceutical companies nationwide in both the efficiency and volume of its specialty generic drug R&D, while also making significant progress in innovative drug research.
Since last year, Shisi Pharmaceutical Group has seized development opportunities, leveraged its innovation chain to accelerate value-chain enhancement, pursued new growth areas, cultivated new competitive advantages, and expedited the market development of high-value-added products with strong growth potential. The dual-circulation strategy—domestic and international—for its specialty formulations and active pharmaceutical ingredients has continued to gain momentum, effectively driving sustained growth in the company’s core business volume and revenue and delivering a series of impressive performance results, thereby significantly accelerating its overall growth trajectory. In the recently released 2021 Top 100 Chinese Pharmaceutical Companies ranking, Shisi Pharmaceutical Group demonstrated marked progress and rapid expansion in innovation capability, scale of operations, market influence, and industry concentration, securing the 59th position on the list—a climb of 13 places from 2020.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091